Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.02.2016 | short review | Ausgabe 1/2016

memo - Magazine of European Medical Oncology 1/2016

Treatment of elderly patients with diffuse large B-cell lymphoma

memo - Magazine of European Medical Oncology > Ausgabe 1/2016
MD Thomas Nösslinger


With the implementation of rituximab, tremendous progress has been achieved in the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, the majority of patients with DLBCL are over the age of 65 years and the management of these patients is often suboptimal. Standard chemo-immunotherapy with curative approach should be appropriate for all elderly patients who can tolerate it. Therefore, a careful evaluation of each patient is mandatory prior to treatment allocation. R- CHOP regimen (rituximab, cyclophosphamide doxorubicin, vincristine, prednisolone) remains the standard of care, but special attention has to be paid to rigorous supportive care. Patients not fit enough for R-CHOP are candidates for dose-reduced therapy or other palliative strategies.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

memo - Magazine of European Medical Oncology 1/2016 Zur Ausgabe